BRIEF published on 04/15/2025 at 10:05, 10 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 10 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 10 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 1 month ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 1 month ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 1 month ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 5 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 02/14/2026 at 01:00, 1 day 17 hours ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 1 day 19 hours ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 2 days ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 2 days 3 hours ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/15/2026 at 16:35, 1 hour 37 minutes ago Arab Palestinian Investment Company (APIC) achieves USD 8.13 million in net income attributable to shareholders and reports record sales of USD 1.31 billion in 2025
Published on 02/15/2026 at 11:43, 6 hours 29 minutes ago EQS-Adhoc: The Management Board of Hapag-Lloyd Aktiengesellschaft confirms negotiations regarding an acquisition of Zim Integrated Shipping Services Ltd.
Published on 02/15/2026 at 11:05, 7 hours 7 minutes ago WePlay Debuts in German Market with "The Little Prince" Special Valentine's Day Collaboration
Published on 02/15/2026 at 09:35, 8 hours 37 minutes ago Canary Islands at the Berlinale European Film Market with more than 40 professionals from the islands
Published on 02/14/2026 at 16:30, 1 day 1 hour ago Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/13/2026 at 18:05, 2 days ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 2 days ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 2 days ago Number of shares and voting rights - January 2026 (In French only)
